RxDoctor Payments Data

Sarah Breaux, MD

Neurology · New Orleans, LANPI 1932631355

Payments from drug & device makers

$4,071in general payments, 2019–2025

Across 97 payments — averaging $41.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • AbbVie$1K
  • Medtronic$767
  • Amneal Pharmaceuticals LLC$253
  • Acadia Pharmaceuticals Inc$192
  • Teva Pharmaceuticals USA, Inc.$121
  • plus $104 from 1 others

What the payments were for

  • Travel & lodging$1,26231%
  • Food & beverage$2,73367%
  • Education$762%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,071 in reported general payments places this provider in the 55th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$34,154
Medicare patients
124
Services billed
478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SkyclarysOmaveloxolone12$387,212
AustedoDeutetrabenazine25$118,686
RytaryCarbidopa/Levodopa39$51,525
NeuproRotigotine22$18,128
Carbidopa-LevodopaCarbidopa/Levodopa587$11,118
Rasagiline Mesylate36$5,064
Carbidopa-Levodopa ErCarbidopa/Levodopa77$3,732
Rivastigmine19$2,784
Entacapone27$2,543
Ropinirole ErRopinirole Hcl17$2,416
Gabapentin161$2,246
Pramipexole DihydrochloridePramipexole Di-Hcl75$1,937
Primidone86$1,815
AmantadineAmantadine Hcl51$1,490
Propranolol Hcl91$1,202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$121$118,68625 claims
Amneal Pharmaceuticals LLCRytary$253$51,52539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 225 neurology providers in Louisiana.

Other neurology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →